/NPCE
NPCE Stock - NeuroPace, Inc.
Healthcare|Medical - DevicesNASDAQ
$16.13-4.61%
$0.78 (-4.61%) • Jan 13
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.96
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).82
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.46
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+16.2%upside
Target: $18.74
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NPCE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.97 – $16.29
TARGET (TP)$18.75
STOP LOSS$14.84
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.86
52W High$18.98
52W Low$7.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $79.91M | $65.42M | $45.52M | $45.18M | $41.14M |
| Gross Profit | $59.09M | $48.12M | $32.49M | $33.44M | $30.27M |
| Gross Margin | 73.9% | 73.6% | 71.4% | 74.0% | 73.6% |
| Operating Income | $-21,671,000 | $-27,174,000 | $-40,794,000 | $-23,737,000 | $-13,051,000 |
| Net Income | $-27,141,000 | $-32,956,000 | $-47,082,000 | $-36,080,000 | $-24,278,000 |
| Net Margin | -34.0% | -50.4% | -103.4% | -79.9% | -59.0% |
| EPS | $-0.93 | $-1.27 | $-1.91 | $-2.17 | $-2.17 |
Company Overview
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NPCEBeat Rate
67%
Last 18 quarters
Avg Surprise
+9.5%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$-0.11
Q4 2025
EPS Surprise History
Q1 24
+30.3%
$-0.23vs$-0.33
Q2 24
0.0%
$-0.32vs$-0.32
Q3 24
+10.3%
$-0.26vs$-0.29
Q4 24
+26.9%
$-0.19vs$-0.26
Q1 25
+28.0%
$-0.18vs$-0.25
Q2 25
+19.2%
$-0.21vs$-0.26
Q3 25
-8.3%
$-0.26vs$-0.24
Q4 25
+45.0%
$-0.11vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.20 | $-0.11 | +45.0% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.26 | $-0.21 | +19.2% | ✓ BEAT |
Q1 2025 | Mar 4, 2025 | $-0.25 | $-0.18 | +28.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.26 | $-0.19 | +26.9% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.29 | $-0.26 | +10.3% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.32 | $-0.32 | 0.0% | = MET |
Q1 2024 | Mar 5, 2024 | $-0.33 | $-0.23 | +30.3% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.39 | $-0.28 | +28.2% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.47 | $-0.36 | +23.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.46 | $-0.41 | +10.9% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-0.49 | $-0.45 | +8.2% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.52 | $-0.48 | +7.7% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.44 | $-0.52 | -18.2% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.46 | $-0.47 | -2.2% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.33 | $-0.44 | -33.3% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.30 | $-0.34 | -13.3% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.39 | $-0.36 | +7.7% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about NPCE
What is NPCE's current stock price?
NeuroPace, Inc. (NPCE) is currently trading at $16.13 per share. The stock has moved -4.61% today.
What is the analyst price target for NPCE?
The average analyst price target for NPCE is $18.75, based on 1 analyst.
What sector is NeuroPace, Inc. in?
NeuroPace, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is NPCE's market cap?
NeuroPace, Inc. has a market capitalization of $0.54 billion, making it a small-cap company.
Does NPCE pay dividends?
No, NeuroPace, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALDX
Aldeyra Therapeutics, Inc.
$4.14
Mkt Cap: $0.2B
BWAY
BrainsWay Ltd.
$23.84
Mkt Cap: $0.5B
CERS
Cerus Corporation
$2.52
Mkt Cap: $0.5B
CVRX
CVRx, Inc.
$6.11
Mkt Cap: $0.2B
DCTH
Delcath Systems, Inc.
$10.42
Mkt Cap: $0.4B
GNLX
Genelux Corporation
$2.74
Mkt Cap: $0.1B
MASS
908 Devices Inc.
$5.37
Mkt Cap: $0.2B
RXST
RxSight, Inc.
$10.11
Mkt Cap: $0.4B
SENS
Senseonics Holdings, Inc.
$7.13
Mkt Cap: $0.3B
SGHT
Sight Sciences, Inc.
$6.83
Mkt Cap: $0.4B
Explore stocks similar to NPCE for comparison